This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Le Carrou, J.
Right arrow Articles by Gautier-Bouchardon, A. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Le Carrou, J.
Right arrow Articles by Gautier-Bouchardon, A. V.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2006, p. 1959-1966, Vol. 50, No. 6
0066-4804/06/$08.00+0     doi:10.1128/AAC.01527-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Persistence of Mycoplasma hyopneumoniae in Experimentally Infected Pigs after Marbofloxacin Treatment and Detection of Mutations in the parC Gene

J. Le Carrou,1 M. Laurentie,2 M. Kobisch,1 and A. V. Gautier-Bouchardon1*

Agence Française de Sécurité Sanitaire des Aliments, Laboratoire d'Etudes et de Recherches Avicoles et Porcines, Unité de Mycoplasmologie-Bactériologie, BP 53, 22440 Ploufragan, France,1 Agence Française de Sécurité Sanitaire des Aliments, Laboratoire d'Etudes et de Recherches sur les Médicaments Vétérinaires et les Désinfectants, Unité de Pharmacocinétique-Pharmacodynamie, BP 90203, 35302 Fougères Cedex, France2

Received 30 November 2005/ Returned for modification 12 January 2006/ Accepted 20 March 2006

The ability of Mycoplasma hyopneumoniae to persist despite fluoroquinolone treatments was investigated with pigs. Groups of specific-pathogen-free pigs were experimentally infected with M. hyopneumoniae strain 116 and treated with marbofloxacin at the therapeutic dose (TD) or half of the therapeutic dose (TD/2) for 3 days. Results showed that, despite tissue penetration of marbofloxacin, particularly in the trachea and the tracheal secretions, the treatments did not have any influence on M. hyopneumoniae recovery from tracheal swabs. Mycoplasmas were also isolated from inner organs and tissues such as liver, spleen, kidneys, and bronchial lymph nodes. Recontamination of pigs via environment could not explain mycoplasma persistence after medication, as decontamination of pigs and allocation to a new disinfected environment did not have any significant effect on the phenomenon. A significant decrease in the susceptibility level to marbofloxacin of 12 mycoplasma clones reisolated after the treatments (TD/2 and TD) was observed. Two point mutations were found in the ParC quinolone resistance-determining region (QRDR) of DNA topoisomerase IV (Ser80->Phe and Asp84->Asn), and one point mutation was observed just behind the QRDR of ParC (Ala116->Glu). This is the first time that mutations in a gene coding for topoisomerase IV have been described for M. hyopneumoniae after in vivo marbofloxacin treatments in experimentally infected pigs. However, development of resistance is not sufficient to explain M. hyopneumoniae persistence in vivo since (i) marbofloxacin concentrations were above the marbofloxacin MIC of the wild-type strain and (ii) mycoplasmas reisolated after a single injection of marbofloxacin did not display an increased marbofloxacin MIC.

* Corresponding author. Mailing address: Agence Française de Sécurité Sanitaire des Aliments, Laboratoire d'Etudes et de Recherches Avicoles et Porcines, Unité de Mycoplasmologie-Bactériologie, BP 53, 22440 Ploufragan, France. Phone: 33-2-96-01-62-86. Fax: 33-2-96-01-62-73. E-mail: a.bouchardon{at}ploufragan.afssa.fr.

Antimicrobial Agents and Chemotherapy, June 2006, p. 1959-1966, Vol. 50, No. 6
0066-4804/06/$08.00+0     doi:10.1128/AAC.01527-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Lysnyansky, I., Mikula, I., Gerchman, I., Levisohn, S. (2009). Rapid Detection of a Point Mutation in the parC Gene Associated with Decreased Susceptibility to Fluoroquinolones in Mycoplasma bovis. Antimicrob. Agents Chemother. 53: 4911-4914 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»